Singapore markets closed

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
43.33+1.54 (+3.69%)
At close: 04:00PM EDT
43.33 0.00 (0.00%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.79
Open42.50
Bid30.99 x 200
Ask43.41 x 100
Day's range41.79 - 43.66
52-week range15.50 - 52.57
Volume808,432
Avg. volume669,972
Market cap2.606B
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

    -- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have bee

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces New Employment Inducement Grants

    BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purch

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

    BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences. David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Thursday, Marc